Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTELO BIOSCIENCES, INC.ARTL · Entity 8413 | Director | July 17, 2026 | July 21, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | November 29, 2024 | December 03, 2024 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTELO BIOSCIENCES, INC.
Report date July 17, 2026 · Filed July 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-07-17 | Direct | 136 |
Reported balance
After 2026-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-17 · Grant · Acquired 136 · Balance 136 F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
HALOZYME THERAPEUTICS, INC.
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,035 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Gift · Disposed 10,470 · Balance 183,035 F1: Represents a bona fide gift to charity. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a bona fide gift to charity.
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2018 Filed May 2, 2018 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 10,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006090 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,751 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2019 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| September 21, 2017 Filed Sep 21, 2017 23:20 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-012575 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,388 F1 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $10.37 | $0.00 |
DisclosureSEC source: 0001179110-17-006946 · edgar.xml · derivative · entry 2 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options became fully vested and exercisable on the date immediately preceding the date of the annual stockholders' meeting following the date of grant. Read SEC document |
| May 08, 2017 Filed May 9, 2017 22:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $10.37 | $103,700.00 |
DisclosureSEC source: 0001179110-17-006946 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:58 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 14,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006701 · edgar.xml · nonDerivative · entry 1 MATSUI CONNIE · CIK 0001236537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,388 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 4, 2018 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.